Diffuse Large B Cell Lymphoma Clinical Trials
10 recruiting trials for Diffuse Large B Cell Lymphoma. Eligibility criteria explained in plain English.
TrialFinderData lists 10 Diffuse Large B Cell Lymphoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 33% (2 studies); the largest phase groups are Phase 2: 2, Phase 1 / Phase 2: 2, Phase 1: 1, Phase 3: 1.
Research is led by Memorial Sloan Kettering Cancer Center (1), OncoNano Medicine, Inc. (1), BeOne Medicines (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Cerebral Spinal Fluid ctDNA (diagnostic_test, 1 trial), followed by ONM-501, Cemiplimab.
Track Diffuse Large B Cell Lymphoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal...
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients...
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or...
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety...
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal...
Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised...
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive,...
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed...
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma
The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut...
Long-term Follow-up Study of Patients Receiving CAR-T Cells
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert...
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as...
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of...
Explore Other Conditions
Frequently Asked Questions
There are currently 10 clinical trials for Diffuse Large B Cell Lymphoma, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Diffuse Large B Cell Lymphoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Diffuse Large B Cell Lymphoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.